{
    "2020-09-16": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Novartis Tafinlar® + Mekinist® demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM",
                "features": {
                    "keywords": [
                        "Tafinlar",
                        "Mekinist",
                        "long-term",
                        "relapse-free",
                        "survival",
                        "benefit",
                        "melanoma"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US",
                "features": {
                    "keywords": [
                        "US Foundation",
                        "commits",
                        "$25M",
                        "health equity",
                        "reducing",
                        "disparities"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "social responsibility"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond",
                "features": {
                    "keywords": [
                        "commitment",
                        "patient access",
                        "pricing",
                        "EUR 1.85 billion",
                        "sustainability-linked",
                        "bond"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Technical Assessment: Bullish in the Intermediate-Term",
                "features": {
                    "keywords": [
                        "Technical Assessment",
                        "Bullish",
                        "Intermediate-Term"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}